Across TCGA pan-cancer cohorts, RTP5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RTP5 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RTP5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RTP5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, LIHC, and LGG are the cancer types where RTP5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.137	0.722	<.001	30	view →
LIHC	OS	Median	All	0.051	0.775	<.001	30	view →
LGG	DFS	Median	All	0.110	0.826	<.001	4	view →
SKCM	DFS	Median	II,III,IV	0.826	0.544	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RTP5 tumor-vs-normal RNA expression · all RTP5 data types